Author:
Abbas Nasir,Javid Farideh,Babar Zaheer-Ud-Din
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Frenoy E. From market authorization to patient access: how long is too long? [Internet]. 2018 [cited 2020 May 18]. Available from: https://globalforum.diaglobal.org/issue/june-2019/from-market-authorization-to-patient-access-how-long-is-too-long/.
2. Payne J. The licensing of new medicines in the UK and approving their use in NHS Scotland. 2012;(Part 2).
3. Abbas N, Hasan SS, Curley L, Babar ZUD. Access to medicines—a systematic review of the literature. Res Soc Adm Pharm. 2019. https://doi.org/10.1016/j.sapharm.2019.12.009.
4. Brhlikova P, Deivanayagam TA, Babar ZU, Osorio-de-Castro CGS, Caetano R, Pollock AM. Essential medicines concept and health technology assessment approaches to prioritising medicines: selection versus incorporation. J Pharm Policy Pract. 2023;16(1):88. https://doi.org/10.1186/s40545-023-00595-4.
5. Butani D, Faradiba D, Dabak SV, Isaranuwatchai W, Huang-Ku E, Pachanee K, Soboon B, Culyer AJ, Teerawattananon Y. Expanding access to high-cost medicines under the Universal Health Coverage scheme in Thailand: review of current practices and recommendations. J Pharm Policy Pract. 2023;16(1):138. https://doi.org/10.1186/s40545-023-00643-z.